Zevra Therapeutics (ZVRA) Competitors $10.61 -0.07 (-0.66%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$10.60 -0.01 (-0.09%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. CPRX, ARQT, IBRX, APGE, TVTX, DNLI, OGN, IDYA, AGIO, and DYNShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Catalyst Pharmaceuticals (CPRX), Arcutis Biotherapeutics (ARQT), ImmunityBio (IBRX), Apogee Therapeutics (APGE), Travere Therapeutics (TVTX), Denali Therapeutics (DNLI), Organon & Co. (OGN), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Catalyst Pharmaceuticals Arcutis Biotherapeutics ImmunityBio Apogee Therapeutics Travere Therapeutics Denali Therapeutics Organon & Co. IDEAYA Biosciences Agios Pharmaceuticals Dyne Therapeutics Zevra Therapeutics (NASDAQ:ZVRA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do analysts prefer ZVRA or CPRX? Zevra Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 126.20%. Catalyst Pharmaceuticals has a consensus target price of $33.20, indicating a potential upside of 58.40%. Given Zevra Therapeutics' higher possible upside, research analysts plainly believe Zevra Therapeutics is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Catalyst Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is ZVRA or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 37.36% compared to Zevra Therapeutics' net margin of 4.33%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics4.33% -112.40% -37.67% Catalyst Pharmaceuticals 37.36%40.78%35.36% Does the media prefer ZVRA or CPRX? In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 8 mentions for Catalyst Pharmaceuticals and 6 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.12 beat Catalyst Pharmaceuticals' score of 0.90 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ZVRA or CPRX? 35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, ZVRA or CPRX? Catalyst Pharmaceuticals has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$62.02M9.60-$105.51M-$0.21-50.52Catalyst Pharmaceuticals$558.50M4.59$163.89M$1.6512.70 Which has more risk & volatility, ZVRA or CPRX? Zevra Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. SummaryCatalyst Pharmaceuticals beats Zevra Therapeutics on 12 of the 17 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$595.59M$3.02B$6.24B$10.67BDividend YieldN/A57.75%5.72%4.81%P/E Ratio-50.5227.5331.1930.71Price / Sales9.60613.11560.36173.93Price / CashN/A168.3237.0861.44Price / Book14.345.6512.056.61Net Income-$105.51M$33.06M$3.33B$277.10M7 Day Performance-1.85%3.16%1.93%2.56%1 Month Performance11.45%8.14%7.77%3.77%1 Year Performance36.90%-2.49%56.40%33.01% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.8704 of 5 stars$10.61-0.7%$24.00+126.2%+34.3%$595.59M$62.02M-50.5220Gap DownCPRXCatalyst Pharmaceuticals4.8424 of 5 stars$20.55+0.1%$33.20+61.6%-2.1%$2.51B$491.73M12.4580News CoverageAnalyst ForecastARQTArcutis Biotherapeutics1.1261 of 5 stars$20.88-0.1%$19.80-5.2%+139.1%$2.51B$196.54M-27.84150News CoverageUpcoming EarningsIBRXImmunityBio3.0757 of 5 stars$2.40-5.1%$10.75+347.9%-41.3%$2.49B$14.74M-5.00590Positive NewsGap UpAPGEApogee Therapeutics2.9846 of 5 stars$55.15+3.3%$92.63+68.0%+2.6%$2.46BN/A-13.3591Analyst ForecastTVTXTravere Therapeutics2.6918 of 5 stars$27.32-0.7%$35.21+28.9%+55.1%$2.45B$233.18M-13.39460News CoverageUpcoming EarningsAnalyst ForecastDNLIDenali Therapeutics4.1766 of 5 stars$16.66-0.4%$33.50+101.1%-39.6%$2.44B$330.53M-5.95430Analyst ForecastOGNOrganon & Co.4.9145 of 5 stars$9.28-1.1%$17.33+86.8%-46.8%$2.44B$6.40B3.454,000News CoveragePositive NewsUpcoming EarningsAnalyst ForecastIDYAIDEAYA Biosciences4.3231 of 5 stars$29.26+5.7%$43.36+48.2%-0.1%$2.43B$7M-7.7280Analyst ForecastAnalyst RevisionHigh Trading VolumeAGIOAgios Pharmaceuticals4.2543 of 5 stars$42.33+2.0%$57.25+35.2%-3.9%$2.41B$36.50M3.85390Upcoming EarningsAnalyst ForecastDYNDyne Therapeutics2.7319 of 5 stars$16.38-0.2%$34.07+108.0%-45.0%$2.34BN/A-4.24100Analyst Forecast Related Companies and Tools Related Companies Catalyst Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives ImmunityBio Alternatives Apogee Therapeutics Alternatives Travere Therapeutics Alternatives Denali Therapeutics Alternatives Organon & Co. Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
